Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DZD6008 |
| Synonyms | |
| Therapy Description |
DZD6008 is a brain-penetrant 4th generation EGFR inhibitor, with activity against EGFR L858R, exon 19 deletions, T790M, and C797 mutations, which potentially induces antitumor activity (J Clin Oncol 2025 43: 16_suppl, 8616). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DZD6008 | DZD 6008|DZD-6008 | EGFR Inhibitor 4th gen 19 | DZD6008 is a brain-penetrant 4th generation EGFR inhibitor, with activity against EGFR L858R, exon 19 deletions, T790M, and C797 mutations, which potentially induces antitumor activity (J Clin Oncol 2025 43: 16_suppl, 8616). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06905197 | Phase I | DZD6008 | A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) | Recruiting | USA | AUS | 0 |